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1. Introduction 
Published clinical accounts of the use of Cyclosporin A (CyA) in renal transplantation 
have recorded a remarkable discordance of results. Calne et al. (1978, 1979a,b, 1981a,b) 
and we (Starzl et aI., 1980, 1981a,b) have become enthusiastic proponents of CyA 
whereas the experiences at the Royal Free Hospital, London (Sweny et aI., 1981) and 
The Peter Bent Brigham Hospital, Boston (Carpenter et aI., 1981) have been dis-
appointing. Problems with drug toxicity have prompted recommendations that CyA 
treatment be restricted to those recipients who have an established postoperative 
diuresis (Caine et aI., 1979a,b, 1981a,b) or that doses be regulated by sophisticated 
pharmacologic and immunologic monitoring (Keown et aI., 1981; Rynasiewicz et al., 
1981; Kahan et aI., 1981). An unresolved controversy has been whether to use Cy A as 
the sole drug as Caine et al. have recommended (1978, 1979a,b, 1981 a,b) or to com-
bine it with steroid therapy from the outset as we have suggested (Starzl et al., 1980, 
1981a,b). This communication will focus on these practical questions, based upon DIU 
experience in treating 104 cadaveric renal recipients. 
2. Graft and patient survival 
2.1. Colorado series 
66 patients were treated from 12 to 21 months ago. Donor-recipients matching was 
random. Deliberate preoperative transfusion was not done. Diabetics and other poor 
risk patients were included. 
9 (13.6%) of the recipients died from 20 to 335 days postoperatively. A detailed 
account of these deaths has been published (Starzl et ai., 1981 b). In brief, three 
failures were from cardiovascular complications not related to immunosuppression and 
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six were caused or contributed to by over immunosuppression with resulting infection 
At autopsy, one of the latter patients was found to have a monoclonal B cel1lymphllmp~ 
(Starzl et aI., 1981 b). 
7 patients were changed from Cy A to azathioprine after 4-13 months, because of 
suspected nephrotoxicity (5 examples), hepatotoxicity (one example) or toxicity of 
both organs (1 example). Two of the grafts were rejected after 2 and 10 weeks, and 
the other 5 have continued to function (usually at an improved level) for 4 weeks to 
more than a year. 
Only 3 of 50 patients who still have grafts have serum creatinine concentrations 
;;;, 3 mg% and their function has been stable between 3 and 4.5 mg%. 
Systematic biopsies were not obtained, but through autopsy, nephrectomy, Or 
biopsy, studies were made of 12 of the 16 lost grafts of which most have been report-
ed (Starzl et aI., 1981 b). Two of the examined kidneys were normal or nearly normal. 
nine had acute and/or chronic rejection and one had been destroyed by recurrent 
oxalosis. There were no findings attributable to Cy A toxicity. A search for the large 
mitochondria described by Mihatsch et al. (1981) in patients under CyA therapy has 
not been made. An increased number of eosinophiles in the cellular infiltrate was the 
only unusual finding. 
2.1.1. Primary cadaveric transplantation (57 cases) 
In this learning period the actual one year graft survival was 45/57 (79%). An addi-
tional graft in a non-compliant patient was lost to rejection after 14 months. Thus, 
44 (77.2%) of the original 57 grafts are still functioning 12-21 months (Fig. 1). These 
results were markedly better than in an old (1976-1977) series of patients treated 
with azathioprine and prednisone, with or without a short course of ineffective ALG, 
at the same institution (Fig. 1). 
2.1.2. Cadaveric retransplantation (9 cases) 
Ten kidneys were placed into nine recipients. One was removed because of complete 
ureteral necrosis, and another graft was placed 6 weeks later. Therapy was stopped in 
three other patients because of a lung abscess, a bleeding duodenal ulcer, and a deep 
wound infection. A few days, or weeks later, their transplanted kidneys were removed. 
Six (67%) of the nine recipients have good renal function after 14-21 months. 
Graft survival is 6/10 (6QG,ih). 
2.2. Pittsburgh series 
38 patients were treated with CyA one to 6 months ago, 21 with primary grafts and 
17 with second or third grafts. Their mean age was 33.3 ± 13.1 (S.D.) years, range 
8-64. All primary recipients were given at least three preoperative transfusions. Dia-
betics and other poor risk candidates were included. An attempt was made at donor-
recipient matching, but this was only marginally successful. The HLA matches ave-
raged 1.3 ± 1.3 (S.D.), and only 7 kidneys were placed which were matched for three 
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Fig. I. Actual one year survival of 57 primary cadaveric renal grafts at the University of Colorado. 
Followup is 12· 21 months. Historical controls are from 1976-77 in whom treatment was with 
azathioprine and prednisone, with or without what proved to be homeopathic ALG. 
or four HLA antigens. In 13 cases, there were no antigens matched. DR matching 
was random. 
12 of 38 patients had antibodies against more than half of a screening lymphocyte 
panel, and in seven of these cases the reactivity was against> 90% of the panel and 
was accounted for mostly by T warm cytotoxic antibodies. Three fourths of the 
recipients with preformed antibodies were in the retransplantation group. In four 
cases (all but one in the retransplantation group) stored recipient sera as recent as 
four weeks completely killed donor lymphocytes, although the crossmatches with sera 
drawn on the day of operation were negative. In many centers, the latter finding is 
interpreted as a positive crossmatch and precludes transplantation. 
There have been no deaths. The only potentially serious complication was Pneumo-
cystis carinii pneumonia which was effectively treated with antibiotics. None of the 
patients were permanently switched from CyA to azathioprine, although this change 
was made for a few days as a therapeutic trial in two patients. 
Only one of the 34 recipients still bearing grafts has a serum creatinine concentra-
tion greater than 3 mg% (the exception is 3.6 mg% and improving.) The average 
creatinines in the primary cadaveric and retransplantation series are given in Table 1. 
Pathologic examination of the four grafts which were removed showed infarction 
in two (due to one example each of early renal artery and renal vein thrombosis) and 
acute and chronic rejection in the other two. The patient with renal vein thrombosis 
had received an ABO incompatible kidney. Needle biopsies of three other grafts were 
obtained because of uncertainty of diagnosis. Two contained mild or moderate signs 
of acute rejection. One had mild glomerulitis. 
368 
2.2.1. Primary cadaveric transplantation (21 cases) 
A kidney from a donor of 'A' blood-type underwent infarction after accideaail 
plantation to a recipient of '0' blood-type. The other 20 (95.2%) are rua*1I 
(Table 1). The ABO incompatibility was an inadvertent violation of the ~ 
protocol, and if this case is thereby excluded the graft survival is 100% (Fig. ~FK 
TABLE 1: University of Pittsburgh series (follow-up is 1-6 months) 
Primary 
Retransplantation 
No. 
21 
17 
Kidneys 
lost 
1* 
3** 
• ABO incompatibility by administrative error. 
Deaths 
o 
o 
• * 2 rejections; one renal artery thrombosis (technical error). 
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Fig. 2. Actuarial survival in University of Pittsburgh primary cadaveric kidney recipients treated 
"'lth CyA and steroids versus azathioprine and prednisone. For the azathioprine-prednisone pa-
tients. historical (1979-80) as well as contemporaneous controls are shown. An additional kidney 
in the CyA group was excluded from analysis because of an administrative accident in which an 
A blood·type kidney was transplanted to an 0 blood-type recipient. 
A contemporaneous trial was conducted of primary cadaveric transplantation in 
19 patients under azathioprine-prednisone. There have been no deaths. The trial 
was randomized except for a few patients in each group. Six (32%) of the azathio-
prine group have lost their grafts and one other has a serum creatinine concentra-
tion of 5.5 mg%. The early results of graft survival on this control group are almost 
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1 those achieved by the University of Pittsburgh team with azathioprine-
..,..uca to 
. e the preceding two years. 
,-drllSO;. ergence between the test and either the contemporaneous or historical 
flit IV ups is so striking (Fig. 2) that is has raised questions about the probity of 
__ 1101 gro .' 
_blluing randomIzation. 
• .. .. Clllial'eric retransplantation . . 
...... f the 17 cadaveric grafts was lost to an early renal artery thrombosIs (techmcal 
01' 0 d two more kidneys were lost to rejection. 14 (82.3%) of the transplants are tfflfF/~ctioning well, after one to six months. The difficulty of achieving these 
~f Uafter retransplantation is discussed later. By prior compassionate agreement, 
..-.u teenth patient was not considered part of this study since she had previously 
II ~first kidney from oxalosis which could not be effectively treated because of 
... aparathyroidism. Her second graft was even more promptly ruined by oxalosis. ~ ncamitant azathioprine-prednisone controls were not obtained. 13 retrans-
..... ~tions were performed at Pittsburgh in. the preceding. two years. 7 (54%) of these 
tpIu had been rejected by the end of the third postoperative month. 
J Sltroids. eyA nephrotoxicity and management 
.. the earlier Colorado CyA series, treatment was in no sense standardized. Ten ofthe 
first patients were pretreated with lymphoid. depletion (nine by thoracic duct drainage 
.... one with peripherallymphopheresis). A number of patients were pretreated with 
C,A for days or weeks. Steroid therapy was withheld initially after transplantation 
.... then often given sporadically or so overzealously that several deaths from infec-
DOll resulted. It was soon evident that significant and sometimes severe rejection often 
CDUId be expected early or late and that confusion of these immunologic events with 
tboIt of Cy A nephrotoxicity could account in part for the eventual poor renal func-
bOn setn by Caine et a1. (1979b) in the majority of his first patients. Biopsy proof of 
Ihc frequency of rejection underCyA therapy was provided by Carpenter et a1. (1981). 
A therapeutic program was suggested (Starzl et a1., 1980, 1981a) and standardized 
($IInl et aI., 1981b). The regimen was designed to minimize diagnostic confusion 
wtIhout resorting to routine biopsy or other instrumentation, to prevent permanent 
-.nage to the new kidney, to avoid jeopardizing the patient with overimmunosuppres-
... and to achieve these ends without the kinds of sophisticated immunologic and 
,eaarmacoiogic monitoring which is available in only a few centers. Mundane though 
II may seem, the last objective will be an important determinant in making Cy A 
tlluable for eventual widespread clinical use in transplanting not only the kidney but 
• tlriety of other organs as well. 
In the following account will be described the evolution of early recovery in the 
ItCCIltly treated Pittsburgh patients who were all treated uniformly at first and who 
Ibcrefore provided data about the incidence of necessary deviation from a recipe 
I 
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approach. For this analysis, the two patients will be excluded who lost their kld.a; 
from an ABO compatibility breach and from a renal artery thrombosis due 10 • 
gical error. Of the 36 remaining patients, 20 were primary cadaveric recipients" 
were undergoing retransplantation. 
3.1. Standard CyA-steroid therapy 
The therapeutic program enacted is simple (Fig. 3). eyA is given orally in I cia. 
17.5 mg/kg, 3-4 h before transplantation, hoping to achieve a good therapeuUC .... 
by the time the new organ is vascularized. The practice is consonant with the ak_"~ 
cokenetic data of Beveridge et aI. (1981) which showed peak plasma leveb ol CJ6 
~ or 6 h after ingestion. 24 h postoperatively the same amount is given. by 
in virtually every patient since postoperative ileus necessitating a parenteral ~ 
rare after renal transplantation. Thereafter, the daily dose of 17.5 mg/kg is Ilft' ___ 
half being taken every 12 h. If there is no subsequent reason to change. the 
daily dose is continued. 
The steroid component of therapy is also preplanned. Just before or dun,. 0,-. 
tion, 1 g of methylprednisolone is given intravenously. Afterwards. the ~lfnff • 
given a five day course of prednisone, starting at 200 mg/day with reou,t .. fI · 
Uji 
::E E 
~ '" a: E 
"'-<II 
'" z ~b 
z'" oE 
",-
0: 
CL 
~~flll 
U E 
- f~ll 
-2 0 4 
'" to 0: 
~ 
U 
<II 
is 
40 YEAR OLD r! 
78.8-+ 83.5kll 
8 12 16 20 24 28 32 36 40 44 
TIME IN DAYS 
Fig. 3. Benign convalescence under CyA-prednisone therapy (Class 1. see text). 
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'd 'each day until on the fifth postoperative day the dose is 40 mg. On the 
.10 ~ ~F the dose is reduced to a maintenance level of 20 mg (Fig. 3). The same 
.lh id a) hedule is used for all adults without consideration of body weight, but for 
~t ~~i1dren the peak dose is started at 100 mg. and the maintenance dose is also 
,..rtdlower. 
I /. Uncomplicated recovery (Class ~F .. . 
J. lescence is untroubled, the pallent IS discharged 10 10-15 days. In a few weeks, 
::;:dnisone can be dropped further (Fig. 3) and after 2 months it can be reduced 
.,.ny adults to 10 mg/day. 
• It. d2y or two after o~eration a renal ~ow s~an is o~tained ~ithK Tc 99m ~qmA or 
other appropriate Isotope. The radlonuchde studies can give Important mferen-
~inflrmation if a differe~~ial diagnosis ~ecome~ neces~ry between rejection. and 
"It. nephrotoxicity. In addlhon, the graft IS exammed With ultrasound to provide a 
..-bne in the event of later trouble. 
In 13 (36.1 %) of the 36 patients, deviations from this early plan were not necess-
- In the outpatient clinic, the CyA dose was eventually lowered to approximately 
~mgKDkg!day (Fig. 3) if there was delayed evidence of renal or liver toxicity, or if 
_r complications such as hirsutism, gum hyperplasia, discoordination or abdomi-
-' dISCOmfort after ingestion of the drug caused patient complaints. Delayed nephro-
1In..:,t)' and hepatotoxicity were indolent in onset and mild in expression as has been 
_ti~d by Klintmalm et al. (I981a,c) from the ~arlier Colorado experience. A se-
,.", creatinine concentration of 2-3 mgClO did not cause alarm and often did not 
lad to a dose change until the end of two months, if then. A normal or near normal 
_ now scan at this time provided assurance of the correctness of the decision 
_ce good flow in conjunction with stable but reduced renal function is most com-
... ible with CyA nephrotoxicity (Starzl et al., 1980; KIintmalm et al., 1981 b). 
J 2. (X&'iations from standard 
ll/. Acute renal failure after initial function (Class II) 
Alter having initial diuresis, 20 (55.5%) of the 36 patients developed a secondary 
4Idine of renal function (Table. 2), usually suddenly (Figs. 4 and 5). The crises 
GCQlITed from a few hours, to two weeks postoperatively, and in 11 cases required 
IIaIpOr3ry return of the patient to dialysis (Fig. 5). Close attention to urinary output 
lIowed the diagnosis to be made before blood chemistry results were available. 
Wound tenderness, graft swelling, and fever were common as previously described 
CStarz.1 et al., 1980). 
The complication was treated immediately as a rejection (Figs. 4 and 5). One gram 
II hydrocortisone was given intravenously and the six day burst of prednisone therapy 
..ct initially was repeated (Figs. 4 and 5), sometimes stopping the stepdown at 
30 m&,day whether or not an unequivocal therapeutic response was obtained (Fig. 5) . 
.. most of these patients 450 rad irradiation at depth was delivered in three doses of 
I 
, ! 
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TABLE 2: Evolution of recovery after 36 cadaveric renal transplantations In Pitt __ 
up 1-6 months) , 
Features of class No. 
Class I Uneventful recovery 13 (36.1%) 
Class II Acute deterioration 20 (55.5%)-
of early function 
Class III Anuria at ouset 3 (8.3%) 3/) 
* 5 of these patients had a initial significant diuresis which began to shut down within I (_ 
most would have been excluded from CyA therapy if a 6 or 12 h urine output of SO naII'_ 
required. 
(,4) 
TIME IN DAYS 
e YEAR OLD ~ 
23kg 
Fig. 4. Class II recovery. with secondary deterioration of graft function which was immediately 
responsive to increased steroid therapy. The clinical diagnosis was rejection. 
150 rad every other day (Figs. 4 and 5). Some of the patients were treated with loW 
doses of heparin. 
Initial diagnostic steps were few and non-invasive. Ultrasound examination was 
obtained to rule out perinephric fluid collection and ureteral obstruction. If radio-
nuclide scans showed poor renal blood flow, the best diagnosis was considered to be 
rejection (Stables et al., 1979). Good renal blood flow, at this time, was considered 
compatible with either a rejection with an excellent prognosis, or CyA nephrotoxicity. 
In most recipients, eyA doses were not immediately adjusted (Fig. 4), particularly 
if there was a good therapeutic response to the steroid therapy. Defmite and quick 
steroid response was observed in 13 of the 20 patients with this syndrome, leading to 
the conclusion that rejection had occurred. If prompt and complete reversal was not ob-
tained, and if repeat scans showed maintenance of good renal blood flow, the strong 
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Fig. 5. Class II recovery which was not promptly responsive to steroid therapy, prompting a reduc· 
tion in Cy A dose. The angiogram showed a patent arterial system with a 'stripped tree' appearance 
of the distal vessels. The biopsy showed glomerulitis. Although oliguria was prolonged, the eventual 
result was good. 
possibility of acute eyA nephrotoxicity was entertained. Daily eyA doses were 
dropped to lO mg/kg or occasionally lower (Fig. 5). Maintenance steroid doses were 
not increased above 30 mg/day and usually they were kept at 20 mg/day. With the 
reasonable (if not low) daily prednisone doses the patients were not ill. 
Failure to see a response to both of the foregoing drug manipulations (6 examples) 
promoted further diagnostic procedures (Fig. 5) including biopsy (5 cases), angio-
graphy (2 cases), and retrograde ureteral catherization (2 cases). All of the biopsied 
kidneys had some evidence of rejection. If no mechanical problems could be found, 
and if the renal biopsy did not show irreversible damage, daily therapy was continued 
with 10 mg/kg of eyA or less and maintenance prednisone doses of 20-30 mg pred-
nisone to which a 1 g dose of hydrocortisone was added every fourth or fifth day. 
4 of the 6 patients who did not respond clearly either to steroid burst therapy or to 
CyA dose reduction finally achieved satisfactory function 2!-5 weeks postoperatively. 
The two grafts which were eventually removed had irrepairable damage from acute and 
chronic rejection. These last two patients were kept on dialysis for 3 and 11 weeks 
before giving up. 
... 
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3.2.2. Immediate anuria (Class III) 
The grafts of three recipients did not function at once (Fig. 6) requiring !)OS ..... 
dialysis 2-5 times. Usually, it was known in advance that there had been k-a 
mia times, or that the flow characteristics were suboptimal in those suspect 
that had been preserved by perfusion. Only one of the three recipients was coa .. 11111 
before operation, to be at immunologic jeopardy from widely reactive T 'tV.,.. 
toxic antibodies and retransplantation. 
For Class III patients, standard therapy was followed (Fig. 6). All three !'tCl .... 
recovered in the usual way after an A TN and were thereafter managed the S&IDI" 
as Class I patients. 
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Fig. 6. Class III convalescence with immediate anuria. The graft was from a 13-year-old donor and 
had warm ischemia for an unknown time (estimated 20-60 min) before cooling with Collins' solu-
tion. Therapy with Cy A and prednisone was by the standard schedule. 
3.2.3. Relation of classes of recovery and retransplantation 
The predominance of Class I patients was in the 20 recipients of primary grafts (Table 
3). Amongst the recipients of primary grafts, the most difficult course was of a woman 
whose current serum had T warm antibodies against> 90% of a lymphocyte panel and 
whose recently stored sera reacted against donor cells. Her kidney became anuric with-
in a few hours, but eventually recovered. 
The high incidence of Class II early renal failure after retransplantation was addi· 
tional evidence for a major immunologic factor in these troublesome but eventually 
manageable patients. If diuresis had been a necessary condition to begin Cy A as in the 
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TABLE 3: Primary versus retransplantation and quality of convalescence 
Primary grafts 
Retransplants 
Total 
20 
16 
Class I 
(sustained 
function) 
9 (45%) 
4 (25%) 
Class II 
(secondary graft 
failure) 
9 (45%) 
11 (69%) 
375 
Class III 
(immediate 
anuria) 
200%) 
1 (6%) 
reported experience of CaIne et a1. (1979b, 1981 a,b), it seems likely that the patients 
most in need of superior immunosuppressive therapy would have been screened out. 
We (Starzl et al., 1980, 1981b) and Rynasiewicz et a1. (1981) have not used this crite· 
rion of selection. 
4. Immunologic and pharmacologic monitoring 
Drs. Paul Terasaki and Yuichi Iwaki of the University of California, Los Angeles, car-
ried out serial immunologic tests in the majority of the Colorado cases. Plasma levels 
of Cy A were performed in selected early patients at the University of Minnesota and 
in later cases at the University of Pittsburgh. 
A statement cannot be made now about the results except to say that they were 
obtained too late to influence clinical management early or late after transplantation. 
II is logical to agree with Keown et al. (1981) and Kahan et al. (1981) that toxic 
lnIf\ifestations of CyA will be accompanied by elevated plasma and blood CyA levels, 
but in future clinical practice, an equally sensitive, more directly relevant and far 
empler guide to appropriate dosage, could be the toxic manifestations themselves. 
Some of our patients have had no complaints despite trough levels of CyA as high as 
1000 ng/ml and others with perfect renal function have had scarcely detectable peak 
ar.m. 
.1 DUc-ussion and Conclusions. 
lac basis of information already available, it seems certain that Cy A will make 
advances in transplantation which were barely conceivable only two or three 
IF. Even during an awkward learning period the actual one year primary cada· 
paft survival in our hands was nearly 80%, and the record with retransplanta· 
.. not far behind. A 13.6% patient mortality, mostly in the first months, was 
_ty to inexperience with CyA and an imperfect understanding of its thera· 
iucraction with steroids. Later, there has been little evidence from the chronic 
thaI graft failures will occur late at a rapid rate or that other complications 
flahibitive. One lymphoma was seen in the nrst 67 patients. Another lympho· 
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proliferative reaction which caused an intestinal perforation after a bout of ...... 
mononucleosis was judged by a number of consultants to be benign (Stant • 
1981b). No other lymphomas have been seen in 71 other recipients of livft'l., 
and kidneys treated by us with Cy A and steroids. 
Applying hard earned lessons in a fresh series, the' early mortality has b«a ..... 
nated with an even higher primary (approaching 100%) and retransplantauoa ... 
survival. The conservative use of steroids with CyA from the time of transpbnu.e 
has allowed protection of graft function and has allowed stepwise adjustments of .... 
agents to be a keen diagnostic tool with the main criteria of diagnosis being the t.t.. 
peutic response to change. However, effective treatment has not depended on ndp 
graft function. The monitoring of immunologic and pharmacologic parameten .. 
undoubtedly yield interesting information but sound clinical management does IIGI 
hinge on such techniques. 
The rapid and sometimes simultaneous drug adjustments in Class II and III palJCfttl 
accommodated both of the possibilities of rejection and CyA nephrotoxicity and thUi 
a fmal inferential diagnosis often could not be made. In any given case. it is not ne~ 
ary to assume that postoperative renal dysfunction is attributable solely to rejectIOn 
or CyA nephrotoxicity. Both factors could and probably do contribute. The con\.-epl 
probably is particularly important for treating patients who start with, or who develop 
intractable oliguria. In such cases. the luxury is lost of correlating graded drug changes 
with therapeutic response. From our experience, it is clear that both rejection and 
nephrotoxicity can be treated by simultaneously increasing steroids and reducing CyA. 
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